Adrenoleukodystrophy Drugs Market in UK - Manufacturing and Consumption, Outlook and Forecast 2020-2026
Adrenoleukodystrophy (ALD) is a rare, genetic, X-linked metabolic disorder caused by mutations in the ABCD1 gene that result in a deficiency in a peroxisomal protein called adrenoleukodystrophy protein (ALDP).
Adrenoleukodystrophy (ALD) is a disease linked to the X chromosome. It is a result of fatty acid buildup caused by the relevant enzymes not functioning properly, which then causes damage to the myelin sheath of the nerves, resulting in seizures and hyperactivity. Other symptoms include problems with speaking, listening, and understanding verbal instructions.
There is currently no satisfactory therapeutic treatment available. Current treatments are limited, namely: Dietary therapy, Gene therapy, Hormone replacement and stem cell transplantation. Hormone replacement is standard for ALD patients demonstrating adrenal insufficiency.
This report contains market size and forecasts of Adrenoleukodystrophy Drugs in UK, including the following market information:
UK Adrenoleukodystrophy Drugs Market Revenue, 2015-2020, 2021-2026, ($ millions)
UK Adrenoleukodystrophy Drugs Market Consumption, 2015-2020, 2021-2026, (K Units)
UK Adrenoleukodystrophy Drugs Production Capacity, 2015-2020, 2021-2026, (K Units)
Top Five Competitors in UK Adrenoleukodystrophy Drugs Market 2019 (%)
The global Adrenoleukodystrophy Drugs market was valued at 258.8 million in 2019 and is projected to reach US$ 456 million by 2026, at a CAGR of 15.2% during the forecast period. While the Adrenoleukodystrophy Drugs market size in UK was US$ XX million in 2019, and it is expected to reach US$ XX million by the end of 2026, with a CAGR of XX% during 2020-2026.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Adrenoleukodystrophy Drugs manufacturers, suppliers, distributors and industry experts on the impacts of the COVID-19 pandemic on businesses, with top challenges including ingredients and raw material delays, component and packaging shortages, reduced/cancelled orders from clients and consumers, and closures of production lines in some impacted areas.
This report also analyses and evaluates the COVID-19 impact on Adrenoleukodystrophy Drugs production and consumption in UK
Total Market by Segment:
UK Adrenoleukodystrophy Drugs Market, By Type, 2015-2020, 2021-2026 ($ millions) & (K Units)
UK Adrenoleukodystrophy Drugs Market Segment Percentages, By Type, 2019 (%)
UK Adrenoleukodystrophy Drugs Market Segment Percentages, By Application, 2019 (%)
The report also provides analysis of leading market participants including:
Total Adrenoleukodystrophy Drugs Market Competitors Revenues in UK, by Players 2015-2020 (Estimated), ($ millions)
Total Adrenoleukodystrophy Drugs Market Competitors Revenues Share in UK, by Players 2019 (%)
Total UK Adrenoleukodystrophy Drugs Market Competitors Sales, by Players 2015-2020 (Estimated), (K Units)
Total UK Adrenoleukodystrophy Drugs Market Competitors Sales Market Share by Players 2019 ($ millions)
Further, the report presents profiles of competitors in the market, including the following:
Adrenoleukodystrophy (ALD) is a disease linked to the X chromosome. It is a result of fatty acid buildup caused by the relevant enzymes not functioning properly, which then causes damage to the myelin sheath of the nerves, resulting in seizures and hyperactivity. Other symptoms include problems with speaking, listening, and understanding verbal instructions.
There is currently no satisfactory therapeutic treatment available. Current treatments are limited, namely: Dietary therapy, Gene therapy, Hormone replacement and stem cell transplantation. Hormone replacement is standard for ALD patients demonstrating adrenal insufficiency.
This report contains market size and forecasts of Adrenoleukodystrophy Drugs in UK, including the following market information:
UK Adrenoleukodystrophy Drugs Market Revenue, 2015-2020, 2021-2026, ($ millions)
UK Adrenoleukodystrophy Drugs Market Consumption, 2015-2020, 2021-2026, (K Units)
UK Adrenoleukodystrophy Drugs Production Capacity, 2015-2020, 2021-2026, (K Units)
Top Five Competitors in UK Adrenoleukodystrophy Drugs Market 2019 (%)
The global Adrenoleukodystrophy Drugs market was valued at 258.8 million in 2019 and is projected to reach US$ 456 million by 2026, at a CAGR of 15.2% during the forecast period. While the Adrenoleukodystrophy Drugs market size in UK was US$ XX million in 2019, and it is expected to reach US$ XX million by the end of 2026, with a CAGR of XX% during 2020-2026.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Adrenoleukodystrophy Drugs manufacturers, suppliers, distributors and industry experts on the impacts of the COVID-19 pandemic on businesses, with top challenges including ingredients and raw material delays, component and packaging shortages, reduced/cancelled orders from clients and consumers, and closures of production lines in some impacted areas.
This report also analyses and evaluates the COVID-19 impact on Adrenoleukodystrophy Drugs production and consumption in UK
Total Market by Segment:
UK Adrenoleukodystrophy Drugs Market, By Type, 2015-2020, 2021-2026 ($ millions) & (K Units)
UK Adrenoleukodystrophy Drugs Market Segment Percentages, By Type, 2019 (%)
- Hormone Replacement
- Transplant
- Others
UK Adrenoleukodystrophy Drugs Market Segment Percentages, By Application, 2019 (%)
- Childhood Cerebral ALD
- Adrenomyeloneuropathy (AMN)
- Addison-only
- Others
The report also provides analysis of leading market participants including:
Total Adrenoleukodystrophy Drugs Market Competitors Revenues in UK, by Players 2015-2020 (Estimated), ($ millions)
Total Adrenoleukodystrophy Drugs Market Competitors Revenues Share in UK, by Players 2019 (%)
Total UK Adrenoleukodystrophy Drugs Market Competitors Sales, by Players 2015-2020 (Estimated), (K Units)
Total UK Adrenoleukodystrophy Drugs Market Competitors Sales Market Share by Players 2019 ($ millions)
Further, the report presents profiles of competitors in the market, including the following:
- Bluebird Bio Inc
- NeuroVia, Inc.
- Orpheris, Inc.
- Minoryx
1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS
1.1 Adrenoleukodystrophy Drugs Market Definition
1.2 Market Segments
1.2.1 Segment by Type
1.2.2 Segment by Application
1.3 UK Adrenoleukodystrophy Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 COVID-19 IMPACT: UK ADRENOLEUKODYSTROPHY DRUGS OVERALL MARKET SIZE
2.1 UK Adrenoleukodystrophy Drugs Market Size: 2020 VS 2026
2.2 UK Adrenoleukodystrophy Drugs Revenue, Prospects & Forecasts: 2015-2026
2.3 UK Adrenoleukodystrophy Drugs Sales (Consumption): 2015-2026
3 COMPANY LANDSCAPE
3.1 Top Adrenoleukodystrophy Drugs Players in UK (including Foreign and Local Companies)
3.2 Top UK Adrenoleukodystrophy Drugs Companies Ranked by Revenue
3.3 UK Adrenoleukodystrophy Drugs Revenue by Companies (including Foreign and Local Companies)
3.4 UK Adrenoleukodystrophy Drugs Sales by Companies (including Foreign and Local Companies)
3.5 UK Adrenoleukodystrophy Drugs Price by Manufacturer (2015-2020)
3.6 Top 3 and Top 5 Adrenoleukodystrophy Drugs Companies in UK, by Revenue in 2019
3.7 UK Manufacturers Adrenoleukodystrophy Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Adrenoleukodystrophy Drugs Players in UK
3.8.1 List of UK Tier 1 Adrenoleukodystrophy Drugs Companies
3.8.2 List of UK Tier 2 and Tier 3 Adrenoleukodystrophy Drugs Companies
4 SIGHTS BY PRODUCT
4.1 Overview
4.1.1 By Type - UK Adrenoleukodystrophy Drugs Market Size Markets, 2020 & 2026
4.1.2 Hormone Replacement
4.1.3 Transplant
4.1.4 Others
4.2 By Type - UK Adrenoleukodystrophy Drugs Revenue & Forecasts
4.2.1 By Type - UK Adrenoleukodystrophy Drugs Revenue, 2015-2020
4.2.2 By Type - UK Adrenoleukodystrophy Drugs Revenue, 2021-2026
4.2.3 By Type - UK Adrenoleukodystrophy Drugs Revenue Market Share, 2015-2026
4.3 By Type - UK Adrenoleukodystrophy Drugs Sales & Forecasts
4.3.1 By Type - UK Adrenoleukodystrophy Drugs Sales, 2015-2020
4.3.2 By Type - UK Adrenoleukodystrophy Drugs Sales, 2021-2026
4.3.3 By Type - UK Adrenoleukodystrophy Drugs Sales Market Share, 2015-2026
4.4 By Type - UK Adrenoleukodystrophy Drugs Price (Manufacturers Selling Prices), 2015-2026
5 SIGHTS BY APPLICATION
5.1 Overview
5.1.1 By Application - UK Adrenoleukodystrophy Drugs Market Size, 2020 & 2026
5.1.2 Childhood Cerebral ALD
5.1.3 Adrenomyeloneuropathy (AMN)
5.1.4 Addison-only
5.1.5 Others
5.2 By Application - UK Adrenoleukodystrophy Drugs Revenue & Forecasts
5.2.1 By Application - UK Adrenoleukodystrophy Drugs Revenue, 2015-2020
5.2.2 By Application - UK Adrenoleukodystrophy Drugs Revenue, 2021-2026
5.2.3 By Application - UK Adrenoleukodystrophy Drugs Revenue Market Share, 2015-2026
5.3 By Application - UK Adrenoleukodystrophy Drugs Sales & Forecasts
5.3.1 By Application - UK Adrenoleukodystrophy Drugs Sales, 2015-2020
5.3.2 By Application - UK Adrenoleukodystrophy Drugs Sales, 2021-2026
5.3.3 By Application - UK Adrenoleukodystrophy Drugs Sales Market Share, 2015-2026
5.4 By Application - UK Adrenoleukodystrophy Drugs Price (Manufacturers Selling Prices), 2015-2026
6 MANUFACTURERS & BRANDS PROFILES
6.1 Bluebird Bio Inc
6.1.1 Bluebird Bio Inc Corporate Summary
6.1.2 Bluebird Bio Inc Business Overview
6.1.3 Bluebird Bio Inc Adrenoleukodystrophy Drugs Major Product Offerings
6.1.4 Bluebird Bio Inc Sales and Revenue in UK (2015-2020)
6.1.5 Bluebird Bio Inc Key News
6.2 NeuroVia, Inc.
6.2.1 NeuroVia, Inc. Corporate Summary
6.2.2 NeuroVia, Inc. Business Overview
6.2.3 NeuroVia, Inc. Adrenoleukodystrophy Drugs Major Product Offerings
6.2.4 NeuroVia, Inc. Sales and Revenue in UK (2015-2020)
6.2.5 NeuroVia, Inc. Key News
6.3 Orpheris, Inc.
6.3.1 Orpheris, Inc. Corporate Summary
6.3.2 Orpheris, Inc. Business Overview
6.3.3 Orpheris, Inc. Adrenoleukodystrophy Drugs Major Product Offerings
6.3.4 Orpheris, Inc. Sales and Revenue in UK (2015-2020)
6.3.5 Orpheris, Inc. Key News
6.4 Minoryx
6.4.1 Minoryx Corporate Summary
6.4.2 Minoryx Business Overview
6.4.3 Minoryx Adrenoleukodystrophy Drugs Major Product Offerings
6.4.4 Minoryx Sales and Revenue in UK (2015-2020)
6.4.5 Minoryx Key News
6.5 MedDay Pharmaceuticals
6.5.1 MedDay Pharmaceuticals Corporate Summary
6.5.2 MedDay Pharmaceuticals Business Overview
6.5.3 MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Major Product Offerings
6.5.4 MedDay Pharmaceuticals Sales and Revenue in UK (2015-2020)
6.5.5 MedDay Pharmaceuticals Key News
7 ADRENOLEUKODYSTROPHY DRUGS PRODUCTION CAPACITY, EXPORT AND IMPORT ANALYSIS
7.1 Adrenoleukodystrophy Drugs Production Capacity and Value in UK, Situation Analysis and Prediction, 2015-2026
7.1.1 UK Adrenoleukodystrophy Drugs Production Capacity, 2015-2026
7.1.2 UK Adrenoleukodystrophy Drugs Production 2015-2026
7.1.3 UK Adrenoleukodystrophy Drugs Production Value 2015-2026
7.2 Key Local Adrenoleukodystrophy Drugs Manufacturers in UK
7.2.1 UK Key Local Adrenoleukodystrophy Drugs Manufacturers Production Capacity
7.2.2 UK Key Local Adrenoleukodystrophy Drugs Manufacturers Production
7.2.3 UK Key Local Adrenoleukodystrophy Drugs Manufacturers Production Value
7.2.4 The Proportion of Adrenoleukodystrophy Drugs Production Sold in UK and Sold Other Than UK by Manufacturers
7.3 Adrenoleukodystrophy Drugs Export and Import in UK
7.3.1 UK Adrenoleukodystrophy Drugs Export Market
7.3.2 UK Adrenoleukodystrophy Drugs Source of Imports
8 COVID-19 IMPACT: KEY MARKET TRENDS, OPPORTUNITY, DRIVERS AND RESTRAINTS
8.1 PESTLE Analysis for UK Adrenoleukodystrophy Drugs Market
8.2 Market Opportunities & Trends
8.3 Market Drivers
8.4 Market Restraints
9 COVID-19 IMPACT ON ADRENOLEUKODYSTROPHY DRUGS SUPPLY CHAIN ANALYSIS
9.1 Supply Chain Analysis
9.2 Upstream Market Analysis
9.3 Downstream and Clients Market Analysis
9.4 Marketing Channels Analysis
9.4.1 Marketing Channels
9.4.2 Adrenoleukodystrophy Drugs Distributors and Sales Agents in UK
10 CONCLUSION
11 APPENDIX
11.1 Note
11.2 Examples of Clients
11.3 Disclaimer
1.1 Adrenoleukodystrophy Drugs Market Definition
1.2 Market Segments
1.2.1 Segment by Type
1.2.2 Segment by Application
1.3 UK Adrenoleukodystrophy Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 COVID-19 IMPACT: UK ADRENOLEUKODYSTROPHY DRUGS OVERALL MARKET SIZE
2.1 UK Adrenoleukodystrophy Drugs Market Size: 2020 VS 2026
2.2 UK Adrenoleukodystrophy Drugs Revenue, Prospects & Forecasts: 2015-2026
2.3 UK Adrenoleukodystrophy Drugs Sales (Consumption): 2015-2026
3 COMPANY LANDSCAPE
3.1 Top Adrenoleukodystrophy Drugs Players in UK (including Foreign and Local Companies)
3.2 Top UK Adrenoleukodystrophy Drugs Companies Ranked by Revenue
3.3 UK Adrenoleukodystrophy Drugs Revenue by Companies (including Foreign and Local Companies)
3.4 UK Adrenoleukodystrophy Drugs Sales by Companies (including Foreign and Local Companies)
3.5 UK Adrenoleukodystrophy Drugs Price by Manufacturer (2015-2020)
3.6 Top 3 and Top 5 Adrenoleukodystrophy Drugs Companies in UK, by Revenue in 2019
3.7 UK Manufacturers Adrenoleukodystrophy Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Adrenoleukodystrophy Drugs Players in UK
3.8.1 List of UK Tier 1 Adrenoleukodystrophy Drugs Companies
3.8.2 List of UK Tier 2 and Tier 3 Adrenoleukodystrophy Drugs Companies
4 SIGHTS BY PRODUCT
4.1 Overview
4.1.1 By Type - UK Adrenoleukodystrophy Drugs Market Size Markets, 2020 & 2026
4.1.2 Hormone Replacement
4.1.3 Transplant
4.1.4 Others
4.2 By Type - UK Adrenoleukodystrophy Drugs Revenue & Forecasts
4.2.1 By Type - UK Adrenoleukodystrophy Drugs Revenue, 2015-2020
4.2.2 By Type - UK Adrenoleukodystrophy Drugs Revenue, 2021-2026
4.2.3 By Type - UK Adrenoleukodystrophy Drugs Revenue Market Share, 2015-2026
4.3 By Type - UK Adrenoleukodystrophy Drugs Sales & Forecasts
4.3.1 By Type - UK Adrenoleukodystrophy Drugs Sales, 2015-2020
4.3.2 By Type - UK Adrenoleukodystrophy Drugs Sales, 2021-2026
4.3.3 By Type - UK Adrenoleukodystrophy Drugs Sales Market Share, 2015-2026
4.4 By Type - UK Adrenoleukodystrophy Drugs Price (Manufacturers Selling Prices), 2015-2026
5 SIGHTS BY APPLICATION
5.1 Overview
5.1.1 By Application - UK Adrenoleukodystrophy Drugs Market Size, 2020 & 2026
5.1.2 Childhood Cerebral ALD
5.1.3 Adrenomyeloneuropathy (AMN)
5.1.4 Addison-only
5.1.5 Others
5.2 By Application - UK Adrenoleukodystrophy Drugs Revenue & Forecasts
5.2.1 By Application - UK Adrenoleukodystrophy Drugs Revenue, 2015-2020
5.2.2 By Application - UK Adrenoleukodystrophy Drugs Revenue, 2021-2026
5.2.3 By Application - UK Adrenoleukodystrophy Drugs Revenue Market Share, 2015-2026
5.3 By Application - UK Adrenoleukodystrophy Drugs Sales & Forecasts
5.3.1 By Application - UK Adrenoleukodystrophy Drugs Sales, 2015-2020
5.3.2 By Application - UK Adrenoleukodystrophy Drugs Sales, 2021-2026
5.3.3 By Application - UK Adrenoleukodystrophy Drugs Sales Market Share, 2015-2026
5.4 By Application - UK Adrenoleukodystrophy Drugs Price (Manufacturers Selling Prices), 2015-2026
6 MANUFACTURERS & BRANDS PROFILES
6.1 Bluebird Bio Inc
6.1.1 Bluebird Bio Inc Corporate Summary
6.1.2 Bluebird Bio Inc Business Overview
6.1.3 Bluebird Bio Inc Adrenoleukodystrophy Drugs Major Product Offerings
6.1.4 Bluebird Bio Inc Sales and Revenue in UK (2015-2020)
6.1.5 Bluebird Bio Inc Key News
6.2 NeuroVia, Inc.
6.2.1 NeuroVia, Inc. Corporate Summary
6.2.2 NeuroVia, Inc. Business Overview
6.2.3 NeuroVia, Inc. Adrenoleukodystrophy Drugs Major Product Offerings
6.2.4 NeuroVia, Inc. Sales and Revenue in UK (2015-2020)
6.2.5 NeuroVia, Inc. Key News
6.3 Orpheris, Inc.
6.3.1 Orpheris, Inc. Corporate Summary
6.3.2 Orpheris, Inc. Business Overview
6.3.3 Orpheris, Inc. Adrenoleukodystrophy Drugs Major Product Offerings
6.3.4 Orpheris, Inc. Sales and Revenue in UK (2015-2020)
6.3.5 Orpheris, Inc. Key News
6.4 Minoryx
6.4.1 Minoryx Corporate Summary
6.4.2 Minoryx Business Overview
6.4.3 Minoryx Adrenoleukodystrophy Drugs Major Product Offerings
6.4.4 Minoryx Sales and Revenue in UK (2015-2020)
6.4.5 Minoryx Key News
6.5 MedDay Pharmaceuticals
6.5.1 MedDay Pharmaceuticals Corporate Summary
6.5.2 MedDay Pharmaceuticals Business Overview
6.5.3 MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Major Product Offerings
6.5.4 MedDay Pharmaceuticals Sales and Revenue in UK (2015-2020)
6.5.5 MedDay Pharmaceuticals Key News
7 ADRENOLEUKODYSTROPHY DRUGS PRODUCTION CAPACITY, EXPORT AND IMPORT ANALYSIS
7.1 Adrenoleukodystrophy Drugs Production Capacity and Value in UK, Situation Analysis and Prediction, 2015-2026
7.1.1 UK Adrenoleukodystrophy Drugs Production Capacity, 2015-2026
7.1.2 UK Adrenoleukodystrophy Drugs Production 2015-2026
7.1.3 UK Adrenoleukodystrophy Drugs Production Value 2015-2026
7.2 Key Local Adrenoleukodystrophy Drugs Manufacturers in UK
7.2.1 UK Key Local Adrenoleukodystrophy Drugs Manufacturers Production Capacity
7.2.2 UK Key Local Adrenoleukodystrophy Drugs Manufacturers Production
7.2.3 UK Key Local Adrenoleukodystrophy Drugs Manufacturers Production Value
7.2.4 The Proportion of Adrenoleukodystrophy Drugs Production Sold in UK and Sold Other Than UK by Manufacturers
7.3 Adrenoleukodystrophy Drugs Export and Import in UK
7.3.1 UK Adrenoleukodystrophy Drugs Export Market
7.3.2 UK Adrenoleukodystrophy Drugs Source of Imports
8 COVID-19 IMPACT: KEY MARKET TRENDS, OPPORTUNITY, DRIVERS AND RESTRAINTS
8.1 PESTLE Analysis for UK Adrenoleukodystrophy Drugs Market
8.2 Market Opportunities & Trends
8.3 Market Drivers
8.4 Market Restraints
9 COVID-19 IMPACT ON ADRENOLEUKODYSTROPHY DRUGS SUPPLY CHAIN ANALYSIS
9.1 Supply Chain Analysis
9.2 Upstream Market Analysis
9.3 Downstream and Clients Market Analysis
9.4 Marketing Channels Analysis
9.4.1 Marketing Channels
9.4.2 Adrenoleukodystrophy Drugs Distributors and Sales Agents in UK
10 CONCLUSION
11 APPENDIX
11.1 Note
11.2 Examples of Clients
11.3 Disclaimer
LIST OF TABLES
Table 1. Key Players of Adrenoleukodystrophy Drugs in UK
Table 2. Top Players in UK, Ranking by Revenue (2019)
Table 3. UK Adrenoleukodystrophy Drugs Revenue by Companies, (US$, Mn), 2015-2020
Table 4. UK Adrenoleukodystrophy Drugs Revenue Share by Companies, 2015-2020
Table 5. UK Adrenoleukodystrophy Drugs Sales by Companies, (K Units), 2015-2020
Table 6. UK Adrenoleukodystrophy Drugs Sales Share by Companies, 2015-2020
Table 7. Key Manufacturers Adrenoleukodystrophy Drugs Price (2015-2020) (US$/Unit)
Table 8. UK Manufacturers Adrenoleukodystrophy Drugs Product Type
Table 9. List of UK Tier 1 Adrenoleukodystrophy Drugs Companies, Revenue (US$, Mn) in 2019 and Market Share
Table 10. List of UK Tier 2 and Tier 3 Adrenoleukodystrophy Drugs Companies, Revenue (US$, Mn) in 2019 and Market Share
Table 11. By Type - Adrenoleukodystrophy Drugs Revenue in UK (US$, Mn), 2015-2020
Table 12. By Type - Adrenoleukodystrophy Drugs Revenue in UK (US$, Mn), 2021-2026
Table 13. By Type - Adrenoleukodystrophy Drugs Sales in UK (K Units), 2015-2020
Table 14. By Type - Adrenoleukodystrophy Drugs Sales in UK (K Units), 2021-2026
Table 15. By Application - Adrenoleukodystrophy Drugs Revenue in UK, (US$, Mn), 2015-2020
Table 16. By Application - Adrenoleukodystrophy Drugs Revenue in UK, (US$, Mn), 2021-2026
Table 17. By Application - Adrenoleukodystrophy Drugs Sales in UK, (K Units), 2015-2020
Table 18. By Application - Adrenoleukodystrophy Drugs Sales in UK, (K Units), 2021-2026
Table 19. Bluebird Bio Inc Corporate Summary
Table 20. Bluebird Bio Inc Adrenoleukodystrophy Drugs Product Offerings
Table 21. Bluebird Bio Inc Adrenoleukodystrophy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2015-2020)
Table 22. NeuroVia, Inc. Corporate Summary
Table 23. NeuroVia, Inc. Adrenoleukodystrophy Drugs Product Offerings
Table 24. NeuroVia, Inc. Adrenoleukodystrophy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2015-2020)
Table 25. Orpheris, Inc. Corporate Summary
Table 26. Orpheris, Inc. Adrenoleukodystrophy Drugs Product Offerings
Table 27. Orpheris, Inc. Adrenoleukodystrophy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2015-2020)
Table 28. Minoryx Corporate Summary
Table 29. Minoryx Adrenoleukodystrophy Drugs Product Offerings
Table 30. Minoryx Adrenoleukodystrophy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2015-2020)
Table 31. MedDay Pharmaceuticals Corporate Summary
Table 32. MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Product Offerings
Table 33. MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2015-2020)
Table 34. Adrenoleukodystrophy Drugs Production Capacity (K Units) of Local Manufacturers in UK, 2015-2020
Table 35. Adrenoleukodystrophy Drugs Production (K Units) of Local Manufacturers in UK, 2015-2020
Table 36. UK Adrenoleukodystrophy Drugs Production Market Share of Local Manufacturers, 2015-2020
Table 37. Adrenoleukodystrophy Drugs Production Value (US$, Mn) of Local Manufacturers in UK, 2015-2020
Table 38. UK Adrenoleukodystrophy Drugs Production Value Market Share of Local Manufacturers, 2015-2020
Table 39. The Percentage of Adrenoleukodystrophy Drugs Production Sold in UK and Sold Other Than UK by Manufacturers
Table 40. The Percentage of Adrenoleukodystrophy Drugs Production Sold in UK and Sold Other Than UK by Manufacturers
Table 41. Dangeguojia Adrenoleukodystrophy Drugs Sales (Consumption), Production, Export and Import, 2015-2020
Table 42. Raw Materials and Suppliers
Table 43. Adrenoleukodystrophy Drugs Downstream Clients in UK
Table 44. Adrenoleukodystrophy Drugs Distributors and Sales Agents in UK
Table 1. Key Players of Adrenoleukodystrophy Drugs in UK
Table 2. Top Players in UK, Ranking by Revenue (2019)
Table 3. UK Adrenoleukodystrophy Drugs Revenue by Companies, (US$, Mn), 2015-2020
Table 4. UK Adrenoleukodystrophy Drugs Revenue Share by Companies, 2015-2020
Table 5. UK Adrenoleukodystrophy Drugs Sales by Companies, (K Units), 2015-2020
Table 6. UK Adrenoleukodystrophy Drugs Sales Share by Companies, 2015-2020
Table 7. Key Manufacturers Adrenoleukodystrophy Drugs Price (2015-2020) (US$/Unit)
Table 8. UK Manufacturers Adrenoleukodystrophy Drugs Product Type
Table 9. List of UK Tier 1 Adrenoleukodystrophy Drugs Companies, Revenue (US$, Mn) in 2019 and Market Share
Table 10. List of UK Tier 2 and Tier 3 Adrenoleukodystrophy Drugs Companies, Revenue (US$, Mn) in 2019 and Market Share
Table 11. By Type - Adrenoleukodystrophy Drugs Revenue in UK (US$, Mn), 2015-2020
Table 12. By Type - Adrenoleukodystrophy Drugs Revenue in UK (US$, Mn), 2021-2026
Table 13. By Type - Adrenoleukodystrophy Drugs Sales in UK (K Units), 2015-2020
Table 14. By Type - Adrenoleukodystrophy Drugs Sales in UK (K Units), 2021-2026
Table 15. By Application - Adrenoleukodystrophy Drugs Revenue in UK, (US$, Mn), 2015-2020
Table 16. By Application - Adrenoleukodystrophy Drugs Revenue in UK, (US$, Mn), 2021-2026
Table 17. By Application - Adrenoleukodystrophy Drugs Sales in UK, (K Units), 2015-2020
Table 18. By Application - Adrenoleukodystrophy Drugs Sales in UK, (K Units), 2021-2026
Table 19. Bluebird Bio Inc Corporate Summary
Table 20. Bluebird Bio Inc Adrenoleukodystrophy Drugs Product Offerings
Table 21. Bluebird Bio Inc Adrenoleukodystrophy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2015-2020)
Table 22. NeuroVia, Inc. Corporate Summary
Table 23. NeuroVia, Inc. Adrenoleukodystrophy Drugs Product Offerings
Table 24. NeuroVia, Inc. Adrenoleukodystrophy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2015-2020)
Table 25. Orpheris, Inc. Corporate Summary
Table 26. Orpheris, Inc. Adrenoleukodystrophy Drugs Product Offerings
Table 27. Orpheris, Inc. Adrenoleukodystrophy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2015-2020)
Table 28. Minoryx Corporate Summary
Table 29. Minoryx Adrenoleukodystrophy Drugs Product Offerings
Table 30. Minoryx Adrenoleukodystrophy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2015-2020)
Table 31. MedDay Pharmaceuticals Corporate Summary
Table 32. MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Product Offerings
Table 33. MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2015-2020)
Table 34. Adrenoleukodystrophy Drugs Production Capacity (K Units) of Local Manufacturers in UK, 2015-2020
Table 35. Adrenoleukodystrophy Drugs Production (K Units) of Local Manufacturers in UK, 2015-2020
Table 36. UK Adrenoleukodystrophy Drugs Production Market Share of Local Manufacturers, 2015-2020
Table 37. Adrenoleukodystrophy Drugs Production Value (US$, Mn) of Local Manufacturers in UK, 2015-2020
Table 38. UK Adrenoleukodystrophy Drugs Production Value Market Share of Local Manufacturers, 2015-2020
Table 39. The Percentage of Adrenoleukodystrophy Drugs Production Sold in UK and Sold Other Than UK by Manufacturers
Table 40. The Percentage of Adrenoleukodystrophy Drugs Production Sold in UK and Sold Other Than UK by Manufacturers
Table 41. Dangeguojia Adrenoleukodystrophy Drugs Sales (Consumption), Production, Export and Import, 2015-2020
Table 42. Raw Materials and Suppliers
Table 43. Adrenoleukodystrophy Drugs Downstream Clients in UK
Table 44. Adrenoleukodystrophy Drugs Distributors and Sales Agents in UK
LIST OF FIGURES
Figure 1. Adrenoleukodystrophy Drugs Segment by Type
Figure 2. Adrenoleukodystrophy Drugs Segment by Application
Figure 3. Dangeguojia Adrenoleukodystrophy Drugs Market Overview: 2020
Figure 4. Key Caveats
Figure 5. Adrenoleukodystrophy Drugs Market Size in UK, (US$, Mn) & (K Units): 2020 VS 2026
Figure 6. UK Adrenoleukodystrophy Drugs Revenue, 2015-2026 (US$, Mn)
Figure 7. Adrenoleukodystrophy Drugs Sales in UK: 2015-2026 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Adrenoleukodystrophy Drugs Revenue in 2019
Figure 9. By Type - UK Adrenoleukodystrophy Drugs Incremental Growth, (US$, Mn), 2015-2026
Figure 10. By Type - UK Adrenoleukodystrophy Drugs Market Share, 2015-2020
Figure 11. By Type - UK Adrenoleukodystrophy Drugs Market Share, 2020-2026
Figure 12. By Type - UK Adrenoleukodystrophy Drugs Price (US$/Unit), 2015-2026
Figure 13. By Application - Adrenoleukodystrophy Drugs Revenue in UK (US$, Mn), 2020 & 2026
Figure 14. By Application - UK Adrenoleukodystrophy Drugs Market Share, 2015-2020
Figure 15. By Application - UK Adrenoleukodystrophy Drugs Market Share, 2020-2026
Figure 16. By Application -UK Adrenoleukodystrophy Drugs Price (US$/Unit), 2015-2026
Figure 17. UK Adrenoleukodystrophy Drugs Production Capacity (K Units), 2015-2026
Figure 18. UK Adrenoleukodystrophy Drugs Actual Output (K Units), 2015-2026
Figure 19. UK Adrenoleukodystrophy Drugs Production Value (US$, Mn), 2015-2026
Figure 20. The Percentage of UK Adrenoleukodystrophy Drugs Export Destination, 2019
Figure 21. The Source of Imports of UK Adrenoleukodystrophy Drugs, 2019
Figure 22. PEST Analysis for UK Adrenoleukodystrophy Drugs Market in 2020
Figure 23. Adrenoleukodystrophy Drugs Market Opportunities & Trends in UK
Figure 24. Adrenoleukodystrophy Drugs Market Drivers in UK
Figure 25. Adrenoleukodystrophy Drugs Market Restraints in UK
Figure 26. Adrenoleukodystrophy Drugs Industry Value Chain
Figure 1. Adrenoleukodystrophy Drugs Segment by Type
Figure 2. Adrenoleukodystrophy Drugs Segment by Application
Figure 3. Dangeguojia Adrenoleukodystrophy Drugs Market Overview: 2020
Figure 4. Key Caveats
Figure 5. Adrenoleukodystrophy Drugs Market Size in UK, (US$, Mn) & (K Units): 2020 VS 2026
Figure 6. UK Adrenoleukodystrophy Drugs Revenue, 2015-2026 (US$, Mn)
Figure 7. Adrenoleukodystrophy Drugs Sales in UK: 2015-2026 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Adrenoleukodystrophy Drugs Revenue in 2019
Figure 9. By Type - UK Adrenoleukodystrophy Drugs Incremental Growth, (US$, Mn), 2015-2026
Figure 10. By Type - UK Adrenoleukodystrophy Drugs Market Share, 2015-2020
Figure 11. By Type - UK Adrenoleukodystrophy Drugs Market Share, 2020-2026
Figure 12. By Type - UK Adrenoleukodystrophy Drugs Price (US$/Unit), 2015-2026
Figure 13. By Application - Adrenoleukodystrophy Drugs Revenue in UK (US$, Mn), 2020 & 2026
Figure 14. By Application - UK Adrenoleukodystrophy Drugs Market Share, 2015-2020
Figure 15. By Application - UK Adrenoleukodystrophy Drugs Market Share, 2020-2026
Figure 16. By Application -UK Adrenoleukodystrophy Drugs Price (US$/Unit), 2015-2026
Figure 17. UK Adrenoleukodystrophy Drugs Production Capacity (K Units), 2015-2026
Figure 18. UK Adrenoleukodystrophy Drugs Actual Output (K Units), 2015-2026
Figure 19. UK Adrenoleukodystrophy Drugs Production Value (US$, Mn), 2015-2026
Figure 20. The Percentage of UK Adrenoleukodystrophy Drugs Export Destination, 2019
Figure 21. The Source of Imports of UK Adrenoleukodystrophy Drugs, 2019
Figure 22. PEST Analysis for UK Adrenoleukodystrophy Drugs Market in 2020
Figure 23. Adrenoleukodystrophy Drugs Market Opportunities & Trends in UK
Figure 24. Adrenoleukodystrophy Drugs Market Drivers in UK
Figure 25. Adrenoleukodystrophy Drugs Market Restraints in UK
Figure 26. Adrenoleukodystrophy Drugs Industry Value Chain
